Parkinson's disease and dopamine transporter neuroimaging: a critical review

Sao Paulo Med J. 2006 May 4;124(3):168-75. doi: 10.1590/s1516-31802006000300014.

Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder that is mainly caused by dopaminergic neuron loss in the substantia nigra. Several nuclear medicine radiotracers have been developed to evaluate PD diagnoses and disease evolution in vivo in PD patients. Positron emission tomography (PET) and single photon computerized emission tomography (SPECT) radiotracers for the dopamine transporter (DAT) provide good markers for the integrity of the presynaptic dopaminergic system affected in PD. Over the last decade, radiotracers suitable for imaging the DAT have been the subject of most efforts. In this review, we provide a critical discussion on the utility of DAT imaging for Parkinson's disease diagnosis (sensitivity and specificity).

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Dopamine Agents
  • Dopamine Plasma Membrane Transport Proteins*
  • Humans
  • Organotechnetium Compounds
  • Parkinson Disease / diagnostic imaging*
  • Positron-Emission Tomography / standards*
  • Sensitivity and Specificity
  • Tomography, Emission-Computed, Single-Photon / standards*
  • Tropanes

Substances

  • Dopamine Agents
  • Dopamine Plasma Membrane Transport Proteins
  • Organotechnetium Compounds
  • Tropanes
  • technetium Tc 99m TRODAT-1